Yunu and WCG announced a partnership in support of WCG’s imaging services.
The University of Hawai‘i Cancer Center and the Queen’s Health Systems will jointly develop oncology clinic space at the UH Cancer Center’s facilities in Kaka‘ako.
Yunu, WCG collaborate to support clinical trial imaging services
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
DeepHealth and ConcertAI’s TeraRecon announced a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow.
Cortechs.ai and EDAP TMS SA announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco Prostate Center.
Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.
Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.
